These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19317360)

  • 1. Management of severe sepsis: role of "bundles".
    Khilnani GC; Hadda V
    Indian J Chest Dis Allied Sci; 2009; 51(1):27-36. PubMed ID: 19317360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the effect of the Surviving Sepsis Campaign treatment guidelines on clinical outcomes in a community hospital.
    Patel GW; Roderman N; Gehring H; Saad J; Bartek W
    Ann Pharmacother; 2010 Nov; 44(11):1733-8. PubMed ID: 20978215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Focal surgery, antibiotic therapy--and then? The role of rhAPC in sepsis].
    Spies C; Otter H; Zuckermann-Becker H; Kox WJ
    Kongressbd Dtsch Ges Chir Kongr; 2002; 119():834-43. PubMed ID: 12704933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options for severe sepsis and septic shock.
    Sharma VK; Dellinger RP
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):395-403. PubMed ID: 16771617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.
    Nguyen HB; Corbett SW; Menes K; Cho T; Daugharthy J; Klein W; Wittlake WA
    Acad Emerg Med; 2006 Jan; 13(1):109-13. PubMed ID: 16365336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.
    Balk RA
    Dis Mon; 2004 Apr; 50(4):168-213. PubMed ID: 15133467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of severe sepsis and septic shock in critically ill patients.
    Namendys-Silva SA; Hernández-Garay M
    Heart Lung; 2012; 41(4):408-9. PubMed ID: 22534210
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study.
    Ferrer R; Artigas A; Suarez D; Palencia E; Levy MM; Arenzana A; Pérez XL; Sirvent JM;
    Am J Respir Crit Care Med; 2009 Nov; 180(9):861-6. PubMed ID: 19696442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of activated protein C (drotrecogin alfa) in a patient with sepsis and respiratory failure on ultra high frequency jet ventilation.
    Datta D; McNamee M
    Conn Med; 2003 Jan; 67(1):11-2. PubMed ID: 12630184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of bundles in sepsis care.
    Hurtado FJ; Nin N
    Crit Care Clin; 2006 Jul; 22(3):521-9, x. PubMed ID: 16893737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The new aspects of treatment of severe sepsis and septic shock].
    Adukauskiene D; Rimdeika R; Vitkauskiene A; Pilvinis V; Cicinskaite I
    Medicina (Kaunas); 2006; 42(4):265-72. PubMed ID: 16687897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendations for management of severe sepsis and septic shock. Surviving sepsis campaign].
    Martin C; Garnier F; Vallet B
    Ann Fr Anesth Reanim; 2005 Apr; 24(4):440-3. PubMed ID: 15826800
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of drotrecogin alfa (activated) in two patients with severe sepsis.
    Mikaszewska-Sokolewicz M; Nierebińska M; Mayzner-Zawadzka E
    Med Sci Monit; 2003 Aug; 9(8):CS80-7. PubMed ID: 12942037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Severe sepsis and septic shock].
    Delaloye J; Baumgartner JD; Calandra T
    Rev Med Suisse; 2006 Apr; 2(60):896-8, 900-2. PubMed ID: 16673720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated protein C and septic shock: a propensity-matched cohort study*.
    Rimmer E; Kumar A; Doucette S; Marshall J; Dial S; Gurka D; Dellinger RP; Sharma S; Penner C; Kramer A; Wood K; Ronald J; Kumar A; Turgeon AF; Houston DS; Zarychanski R;
    Crit Care Med; 2012 Nov; 40(11):2974-81. PubMed ID: 22932397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
    Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
    Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with severe sepsis and septic shock: real-life lessons.
    Davidow JS; Brindley PG; Jacka MJ; Gibney RT
    CJEM; 2006 Jul; 8(4):244-5. PubMed ID: 17324301
    [No Abstract]   [Full Text] [Related]  

  • 18. Activated protein C (Xigris) treatment in sepsis: a drug in trouble.
    Gårdlund B
    Acta Anaesthesiol Scand; 2006 Sep; 50(8):907-10. PubMed ID: 16923083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drotrecogin alfa (activated) for nonmenstrual toxic shock syndrome associated with methicillin resistant Staphylococcus aureus infection.
    Haddadin DW; Samnani IQ; Moorman JP
    South Med J; 2006 Nov; 99(11):1295-6. PubMed ID: 17195430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe sepsis and septic shock: review of the literature and emergency department management guidelines.
    Nguyen HB; Rivers EP; Abrahamian FM; Moran GJ; Abraham E; Trzeciak S; Huang DT; Osborn T; Stevens D; Talan DA;
    Ann Emerg Med; 2006 Jul; 48(1):28-54. PubMed ID: 16781920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.